Sab biotherapeutics regains compliance with nasdaq minimum bid price requirement

Sioux falls, s.d., jan. 23, 2024 (globe newswire) -- sab biotherapeutics , inc. (nasdaq: sabs ), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that it received notice from the nasdaq stock market llc ("nasdaq") on january 23, 2024 informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the "rule") for continued listing on the nasdaq capital market.
SABS Ratings Summary
SABS Quant Ranking